423 related articles for article (PubMed ID: 15073846)
21. Abnormal fragile histidine triad (FHIT) expression in advanced cervical carcinoma: a poor prognostic factor.
Krivak TC; McBroom JW; Seidman J; Venzon D; Crothers B; MacKoul PJ; Rose GS; Carlson JW; Birrer MJ
Cancer Res; 2001 Jun; 61(11):4382-5. PubMed ID: 11389064
[TBL] [Abstract][Full Text] [Related]
22. Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2gamma expression levels correlate with basal phenotype in breast cancer.
Guler G; Huebner K; Himmetoglu C; Jimenez RE; Costinean S; Volinia S; Pilarski RT; Hayran M; Shapiro CL
Cancer; 2009 Feb; 115(4):899-908. PubMed ID: 19130459
[TBL] [Abstract][Full Text] [Related]
23. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors.
Greenspan DL; Connolly DC; Wu R; Lei RY; Vogelstein JT; Kim YT; Mok JE; Muñoz N; Bosch FX; Shah K; Cho KR
Cancer Res; 1997 Nov; 57(21):4692-8. PubMed ID: 9354423
[TBL] [Abstract][Full Text] [Related]
24. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer.
Bednarek AK; Laflin KJ; Daniel RL; Liao Q; Hawkins KA; Aldaz CM
Cancer Res; 2000 Apr; 60(8):2140-5. PubMed ID: 10786676
[TBL] [Abstract][Full Text] [Related]
25. Components of DNA damage checkpoint pathway regulate UV exposure-dependent alterations of gene expression of FHIT and WWOX at chromosome fragile sites.
Ishii H; Mimori K; Inageta T; Murakumo Y; Vecchione A; Mori M; Furukawa Y
Mol Cancer Res; 2005 Mar; 3(3):130-8. PubMed ID: 15798093
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of fragile histidine triad expression in tumors from saudi arabia: a tissue microarray analysis.
Bavi P; Jehan Z; Atizado V; Al-Dossari H; Al-Dayel F; Tulbah A; Amr SS; Sheikh SS; Ezzat A; El-Solh H; Uddin S; Al-Kuraya K
Cancer Epidemiol Biomarkers Prev; 2006 Sep; 15(9):1708-18. PubMed ID: 16985034
[TBL] [Abstract][Full Text] [Related]
27. [Loss of fragile histidine triad expression and metastasis in breast cancer].
Zhao P; Li XY; Chen LZ
Ai Zheng; 2002 Jun; 21(6):668-70. PubMed ID: 12452072
[TBL] [Abstract][Full Text] [Related]
28. Abnormal fragile histidine triad (Fhit) expression in invasive cervical adenocarcinoma: association with tumor aggressiveness.
Yoon SO
Hum Pathol; 2007 Feb; 38(2):326-31. PubMed ID: 17137614
[TBL] [Abstract][Full Text] [Related]
29. Fragile histidine triad gene abnormalities in the pathogenesis of gallbladder carcinoma.
Wistuba II; Ashfaq R; Maitra A; Alvarez H; Riquelme E; Gazdar AF
Am J Pathol; 2002 Jun; 160(6):2073-9. PubMed ID: 12057912
[TBL] [Abstract][Full Text] [Related]
30. WWOX expression in different histologic types and subtypes of non-small cell lung cancer.
Donati V; Fontanini G; Dell'Omodarme M; Prati MC; Nuti S; Lucchi M; Mussi A; Fabbri M; Basolo F; Croce CM; Aqeilan RI
Clin Cancer Res; 2007 Feb; 13(3):884-91. PubMed ID: 17289881
[TBL] [Abstract][Full Text] [Related]
31. Prognostic relevance of fragile histidine triad protein expression in patients with small cell lung cancer.
Rohr UP; Rehfeld N; Geddert H; Pflugfelder L; Bruns I; Neukirch J; Rohrbeck A; Grote HJ; Steidl U; Fenk R; Opalka B; Gabbert HE; Kronenwett R; Haas R
Clin Cancer Res; 2005 Jan; 11(1):180-5. PubMed ID: 15671544
[TBL] [Abstract][Full Text] [Related]
32. Alterations of the FHIT gene in breast cancer: association with tumor progression and patient survival.
Ingvarsson S; Sigbjornsdottir BI; Huiping C; Jonasson JG; Agnarsson BA
Cancer Detect Prev; 2001; 25(3):292-8. PubMed ID: 11425271
[TBL] [Abstract][Full Text] [Related]
33. The fragile histidine triad/common chromosome fragile site 3B locus and repair-deficient cancers.
Turner BC; Ottey M; Zimonjic DB; Potoczek M; Hauck WW; Pequignot E; Keck-Waggoner CL; Sevignani C; Aldaz CM; McCue PA; Palazzo J; Huebner K; Popescu NC
Cancer Res; 2002 Jul; 62(14):4054-60. PubMed ID: 12124341
[TBL] [Abstract][Full Text] [Related]
34. Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer.
Burke L; Khan MA; Freedman AN; Gemma A; Rusin M; Guinee DG; Bennett WP; Caporaso NE; Fleming MV; Travis WD; Colby TV; Trastek V; Pairolero PC; Tazelaar HD; Midthun DE; Liotta LA; Harris CC
Cancer Res; 1998 Jun; 58(12):2533-6. PubMed ID: 9635574
[TBL] [Abstract][Full Text] [Related]
35. FHIT gene and flanking region on chromosome 3p are subjected to extensive allelic loss in Egyptian breast cancer patients.
Ismail HM; Medhat AM; Karim AM; Zakhary NI
Mol Carcinog; 2011 Aug; 50(8):625-34. PubMed ID: 21557333
[TBL] [Abstract][Full Text] [Related]
36. Loss of Fhit expression is a predictor of poor outcome in tongue cancer.
Lee JI; Soria JC; Hassan K; Liu D; Tang X; El-Naggar A; Hong WK; Mao L
Cancer Res; 2001 Feb; 61(3):837-41. PubMed ID: 11221865
[TBL] [Abstract][Full Text] [Related]
37. Reduced acetylated histone H4 is associated with promoter methylation of the fragile histidine triad gene in resected esophageal squamous cell carcinoma.
Tzao C; Sun GH; Tung HJ; Hsu HS; Hsu WH; Wang YC; Cheng YL; Lee SC
Ann Thorac Surg; 2006 Aug; 82(2):396-401; discussion 401. PubMed ID: 16863736
[TBL] [Abstract][Full Text] [Related]
38. Downregulation of the potential suppressor gene IGFBP-rP1 in human breast cancer is associated with inactivation of the retinoblastoma protein, cyclin E overexpression and increased proliferation in estrogen receptor negative tumors.
Landberg G; Ostlund H; Nielsen NH; Roos G; Emdin S; Burger AM; Seth A
Oncogene; 2001 Jun; 20(27):3497-505. PubMed ID: 11429696
[TBL] [Abstract][Full Text] [Related]
39. Loss of Fhit protein expression in high-grade and advanced stage endometrial carcinomas.
Yura Y; Mandai M; Konishi I; Hamid AA; Tsuruta Y; Kusakari T; Fujii S
Anticancer Res; 2003; 23(3C):2837-43. PubMed ID: 12926121
[TBL] [Abstract][Full Text] [Related]
40. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
